Celldex Therapeutics General and Administrative Expenses 2011-2026 | CLDX

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Celldex Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
38.5 M	30.9 M	27.2 M	20.5 M	14.5 M	15.4 M	19.3 M	25 M	36 M	33.8 M	20.6 M	14.8 M	10 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
38.5 M	10 M	23.6 M

Quarterly General and Administrative Expenses Celldex Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10.7 M	10.4 M	10.8 M	-	10.1 M	9.13 M	9.1 M	-	8.22 M	7.22 M	6.64 M	-	6.53 M	7.15 M	6.91 M	-	5.82 M	4.31 M	4.12 M	-	3.64 M	3.53 M	3.67 M	-	3.4 M	3.91 M	4.9 M	-	3.72 M	5.62 M	5.59 M	-	5.35 M	6.53 M	7.23 M	-	6.95 M	7.79 M	9.31 M	-	8.49 M	8.18 M	6.09 M	-	5 M	4.79 M	4.58 M	-	3.58 M	3.41 M	3.14 M	-	2.84 M	2.22 M	2.32 M	-	2.27 M	2.24 M	2.34 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
10.8 M	2.22 M	5.77 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Biogen BIIB	2.4 B	$ 172.65	0.62 %	$ 25.1 B	USA
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	14.4 M	$ 2.38	-4.22 %	$ 134 M	China
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
BioNTech SE BNTX	286 M	$ 117.22	1.07 %	$ 27.2 B	Germany
Aptorum Group Limited APM	5.41 M	$ 0.98	1.35 %	$ 5.34 M	China
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.62	1.91 %	$ 8.71 B	Australia
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Catalyst Biosciences CBIO	14.7 M	$ 12.1	-5.47 %	$ 797 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
BioXcel Therapeutics BTAI	34.5 M	$ 1.78	-2.47 %	$ 4.51 M	USA
BioLineRx Ltd. BLRX	4.31 M	$ 3.05	-1.77 %	$ 908 M	Israel
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Ascendis Pharma A/S ASND	160 M	$ 232.9	-1.06 %	$ 5 B	Danmark
Burford Capital Limited BUR	99.3 M	$ 9.73	-0.21 %	$ 1.57 B	Britain
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Cellectis S.A. CLLS	37.9 M	$ 4.21	-4.84 %	$ 116 M	France
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Arrowhead Pharmaceuticals ARWR	124 M	$ 67.14	0.13 %	$ 8.98 B	USA
Compugen Ltd. CGEN	10.9 M	$ 2.05	-1.91 %	$ 184 M	Israel
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 4.4	-2.87 %	$ 9.57 B	Israel
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	45.8 M	-	-	$ 1.01 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Adaptimmune Therapeutics plc ADAP	73.5 M	-	-15.15 %	$ 60.3 M	Britain
Amphastar Pharmaceuticals AMPH	56.7 M	$ 26.56	2.45 %	$ 1.29 B	USA
Coherus BioSciences CHRS	192 M	$ 2.25	9.22 %	$ 212 M	USA
Amneal Pharmaceuticals AMRX	476 M	$ 13.58	1.42 %	$ 4.2 B	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Athira Pharma ATHA	26.1 M	-	-	$ 269 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	17.4 M	$ 2.75	1.84 %	$ 17.3 M	USA
AstraZeneca PLC AZN	15.2 B	$ 94.2	1.34 %	$ 96.9 B	Britain
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA